|
|
||||||||
1From the NIDCD/NEI, National Institutes of Health, Bethesda, Maryland; 2Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan; 3Biological Imaging Core, National Eye Institute, Bethesda, Maryland; 4Laboratory of Membrane Biochemistry and Biophysics, NIAAA, Bethesda, Maryland; and the 5Department of Ophthalmics Research, Merck Research Laboratories, West Point, Pennsylvania.
| Abstract |
|---|
|
|
|---|
METHODS. A construct targeted to exon 2 of the Elovl4 gene was used to suppress expression of the gene. Elovl4 homozygous pups were nonviable and were not available for study. Hence, the analysis was performed on heterozygous Elovl4+/ mice 16 to 22 month of age and littermate wild-type (WT) control mice of the same age. Characterization included examining gene message and protein levels, electroretinogram (ERG), retinal morphology and ultrastructure, and plasma and retinal fatty acid composition.
RESULTS. Although the level of Elovl4 mRNA was reduced in Elovl4+/ retinas, only minimal morphologic abnormalities were found, and the retinal (ERG) function was essentially normal in Elovl4+/ retinas compared with the WT control retinas. Systemic fatty acid profiles of Elovl4+/ mice were unremarkable, although the concentration of several fatty acids was significantly lower in Elovl4+/ retinas, particularly the monounsaturated fatty acids.
CONCLUSIONS. The detailed characterization of this animal model provides the first in vivo evidence that Elovl4 haploinsufficiency is not the underlying key disease mechanism in STGD3. The results are consistent with a dominant negative mechanism for the deletion mutation. The Elovl4 knockout mouse is one of three complementary animal models that will help elucidate the disease mechanism.
The importance of ELOVL4 protein is implied by its evolutionary conservation. Human ELOVL4 encodes a protein of 314 amino acids with approximately 35% amino acid identity to members of the ELO protein family in yeast,5 and orthologues have been identified in other species, including Caenorhabditis elegans, zebrafish, and chicken.15 16 17 18 The cellular function of ELOVL4 is unknown, but homology with yeast proteins suggests that it is an ER-bound transmembrane protein associated with LCFA synthesis.5
LC polyunsaturated fatty acids (PUFAs) from the n-6 and n-3 classes are essential for brain and retinal development and for visual function.19 An important role for docosahexaenoic acid (DHA) within the retina is suggested by its high levels and active conservation in this tissue.5 20 21 ELOVL4 is expressed in rod and cone photoreceptor cells and is probably involved in one of the elongation steps necessary for fatty acid biosynthesis.5 20 21 22 23 The essential role of ELOVL4 in polyunsaturated fatty acids (PUFA) synthesis is also suggested by preliminary evidence of improved visual function in human STGD3 disease with supplementation of DHA.24 Another recent study found that phenotypic severity in a family with STGD3 disease correlates with dietary fatty acid intake, and that a high dietary intake of DHA may partially ameliorate the maculopathy.25
We characterized heterozygous animals in a mouse model with a targeted deletion of Elovl4, to further understand the role of this gene in macular degeneration.
| Methods |
|---|
|
|
|---|
|
Genotyping
Elovl4+/ mice were genotyped by PCR methods using tail DNA as a template, with a set of three oligonucleotide primers: M700KP-WT (5'-CTCCGCAGATAAACGTGTAGCAGAC-3'), M700KP-S (5'-AGAGTGCCGTTAACAAACCTACCTC-3'), and Neo3196 (5'-GGGTGGGATTAGATAAATGCCTGCTCT-3'). The M700KP-WT paired with M700KP-S was used to amplify the wild-type allele; M700KP-WT paired with Neo3196 was used to identify the targeted allele. PCR was performed in a 25-µL reaction volume containing 100 ng of tail DNA, 200 µM deoxynucleotide triphosphates, 250 nM of each primer, 2.5 mM MgCl2, 1.25 units of Taq DNA polymerase, and 2.5 µL of 10x reaction buffer. The PCR conditions were 3 minutes at 95°C for initial denaturation, followed by 35 cycles of 30 seconds at 95°C, 50 seconds at 60°C, 50 seconds at 72°C, and 5 minutes at 72°C for the final extension. The targeted allele gave rise to a 406-bp PCR fragment, and the wild-type allele produced a 217-bp fragment. The PCR products were analyzed by agarose gel electrophoresis.
Electroretinograms
The electroretinogram (ERG) was recorded from six Elovl4+/ 16-month-old mice and four age-matched control littermate wild-type (WT) mice. The mice were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg) and xylazine (4 mg/kg), and body temperature was maintained by placing them on a heating pad. The pupils were fully dilated with topical corneal 0.5% tropicamide and 2.5% phenylephrine HCl, and both eyes were recorded simultaneously using corneal gold-wire loops as the active electrodes with 0.5% proparacaine hydrochloride topical anesthesia. Gold-wire electrodes were placed on the sclera near the limbus, to serve as reference electrodes. A neutral wire was attached to the ear. ERG stimuli were xenon photostrobe 10-µs flashes with 0.6 log cds/m2 maximum intensity in a full-field integrating sphere. Scotopic responses were recorded across a 7-log-unit range of stimulus intensity in 0.5-log-unit steps beginning from below threshold up to maximum intensity, amplified, and filtered (5000 gain, 0.11000 Hz). For photopic recordings a constant white background light of 34 cd/m2 was used to suppress rod function.
Dark-adapted and light-adapted a-wave amplitudes were measured from the baseline to the response peak, and b-wave amplitudes were measured from the baseline or from the a-wave trough when the a-wave was present. Data were analyzed by the MIXED procedure (PROC MIXED, SAS for Windows, ver. 9.1; SAS Institute, Inc., Cary, NC), which is used for analysis of repeated-measures data. It fits a variety of mixed linear models to the data and extends the general linear model by allowing a more flexible specification of variance and covariance. The primary ERG outcome variables were log amplitudes of the a- and b-wave responses compared between Elovl4+/ and control eyes. Predictor variables were ERG stimulus intensity and group.
Lipid Extraction and Fatty Acid Analysis
Retinas of 10 Elovl4+/ and 4 control littermate mice, all at 19 to 22 months of age, were removed and stored at 80°C. Retinas were weighed and lipid extraction performed according to the method of Bligh and Dyer.26 To each sample, 50 µg butylated hydroxytoluene (BHT) was added along with the internal standard 22:3n-3 methyl ester (1 µg/mg retina wet weight). Retinas were subsequently transmethylated using the BF3-methanol method of Morrison and Smith27 as modified by Salem et al.28 with the cosolvent hexane. The methyl ester samples were analyzed by gas chromatography as previously described,28 except that the retinas were injected using a splitless method in which 2 µL of the hexane extract was injected, the purge flow rate to the split vent was 14 mL/min, and the valve was opened 0.25 minute after injection. Fatty acid analysis was also performed on plasma samples of all 10 animals. The plasma samples were extracted as previously described by Folch et al.29 and transmethylated as described by Salem et al.28
Tissue Processing for Light and Electron Microscopy
Four Elovl4+/ and two littermate control WT mice, all 17 to 19 months of age, were euthanatized, and the eyes were enucleated. A shallow incision was made through the cornea at the limbus, and the eyes were immersed overnight in primary fixative: 2% formaldehyde (from electron microscopy [EM] grade paraformaldehyde) + 2% glutaraldehyde in 0.086 M sodium phosphate buffer (pH 7.2). The next day, the anterior segment and lens were removed. Eyecups were washed in cold, 0.137 M sodium phosphate buffer and transferred to capped vials containing 1% osmium tetroxide in sodium phosphate buffer for 1 hour. Eyecups were washed in chilled distilled water and serially dehydrated in an ethanol series (30%100%) on ice. Eyes were transferred from absolute ethanol to propylene oxide for 20 minutes and then infiltrated with a 1:1 mixture of propylene oxide and Araldite 6005 for 24 hours. After infiltration, eyes were embedded in Araldite 6005.
For light microscopy, 1-µm-thick sections were cut with a glass knife through the center of the globe, without regard to orientation about the optical axis of the eye, and were stained with 1% toluidine blue/methylene blue/azure II. Sections were examined with a microscope (BX51; Olympus, Lake Success, NY) and 40x objective and were photographed with a digital camera. Measurements of outer nuclear layer (ONL) width and rod outer segment (ROS) length were made in two peripheral fields approximately 300 µm from each edge, in two midperipheral fields half-way to the central retina and finally in the central field. For ROS length, the maximum and minimum lengths in each field were averaged.
For EM, thin sections (
100 nm) were collected on 200 hex copper grids, stained with 2% aqueous uranyl acetate and Reynolds lead citrate, and examined by transmission electron microscope (model 1010; JEOL, Tokyo, Japan).
RNA and Protein Isolation and cDNA Preparation
Retinal RNA was isolated (TRIzol reagent; Invitrogen Corp, Carlsbad, CA), and protein was isolated simultaneously from the phenol phase after removal of the aqueous phase containing RNA, both according to the manufacturers protocol. Total RNA was treated with RNase-free DNase, to remove the genomic DNA contamination, and purified (RNeasy minikit; Qiagen, Valencia, CA). First-strand cDNA was synthesized for RT-PCR (SuperScript First-Strand Synthesis System; Invitrogen Corp.).
Real-Time Quantitative RT-PCR
All real-time PCR (qRT-PCR) primer pairs were designed so that one primer was located in one exon, and the second primer was in a different exon, resulting in an intron-spanning amplification event that could distinguish amplification of reverse-transcribed RNA from genomic DNA21 (Fig. 1) . Quantitative PCR and melting curve analyses were performed (iQ SYBR Green Supermix and iCycler; Bio-Rad, Hercules, CA). Expression of four housekeeping genesGapdh, Hgprt, Actin-b, and RpL19was used as the control, to normalize and validate the expression data. The relative quantity of expression was calculated by the comparative Ct (threshold cycle) method for each of the housekeeping genes, as described previously.21 The expression data are presented as a percentage of the relative value of the age-matched controls.30 Samples from four Elovl4+/ mice and three C57BL/6 control animals, all at 19 to 22 months of age, were analyzed.
Western Blot Analysis
Protein isolation and Western blot analysis were performed as previously described18 with the same four Elovl4+/ and three C57BL/6 control retinas used for qRT-PCR. Total protein quantity was measured with the bicinchoninic acid (BCA) reagent (Pierce, Rockford, IL), and equal quantities were resolved on 10% SDS-PAGE. Western blot analysis was performed using a rabbit polyclonal anti-ELOVL4 antibody generated against the synthetic peptide corresponding to internal sequence amino acids (107-121) in exon 3 of human ELVOL4. This antibody, available through Abcam (Cambridge, MA), has been tested and found to cross-react with ELVOL4 from mouse tissues (1:500 dilution). Signal was detected with chemiluminescence (ECL Kit; Amersham Biosciences, Piscataway, NJ), according to the manufacturers instructions.
| Results |
|---|
|
|
|---|
The Elovl4+/ mice were not different from littermate control WT mice in weight, apparent behavior, or longevity. Semiquantitative (q)RT-PCR analysis of retinal cDNA from Elovl4 +/ mice with primers designed to amplify Elovl4 mRNA confirmed the presence of message from the WT Elovl4 gene. However, the WT Elovl4 message level was reduced to 10% to 25% of the expression in age-matched C57BL/6 mice (Fig. 2A) . On a Western blot, the anti-ELOVL4 antibody detected a single band of the expected size (37 kDa) in both Elovl4+/ and C57BL/6 control retina, indicating expression of the WT ELOVL4 protein in the Elovl4+/ retina (Fig. 2C) . Despite the considerable reduction in Elovl4 message, the morphologic appearance of the retina in the Elovl4+/ mice was minimally different from age-matched littermate WT mice (Fig. 3A) . The photoreceptor outer nuclear layer (ONL) was at most only 1 to 2 cells thinner in some areas of the retina in the Elovl4+/ mice, and measurements of ONL width indicated only minimal thinning of 10% ± 7.9% (mean ± SD, n = 5), with no statistical significance at any region (Fig. 3B) . The ROS of Elovl4+/ mice were shorter than the WT by an average of 20% ± 18% (mean ± SD, n = 5, P < 0.01 in the PROCMIXED procedure) across the retina (Fig. 3B) . Rhodopsin message level was 33% lower in four Elovl4+/ retinas relative to aged-matched C57BL/6 mice (Fig. 2B) , but was not statistically significant (P = 0.36) indicating that, overall, there was no detectable loss of photoreceptors at this advanced age by this method. The Elovl4+/ retinas showed scattered regions in which apoptotic photoreceptor nuclei were present and rod outer segments were less densely packed.
|
|
|
ERGs were recorded from 16-month-old Elovl4+/ mice and littermate WT control animals to evaluate retinal function (Fig. 5) . Dark-adapted a- and b-wave amplitudes were both consistently larger in the Elovl4+/ mice than in the WT mice, although the difference was statistically significant at only one stimulus intensity (Figs. 5A 5B) . When all points of the entire intensity response curve were analyzed together by the "mixed procedure" method, no significant difference was found between the groups. Similarly, the b-wave amplitudes of the light-adapted responses were consistently larger in the Elovl4+/ mice for all stimulus intensities, but the results were not statistically different from WT (Figs. 5A 5C) . No differences in wave shape or implicit time were observed. Hence, one can conclude that the Elovl4+/ responses were definitively not reduced compared with WT, despite the slight decrease in ROS length. We also examined the fundus of five 17- to 19-month-old Elovl4+/ mice by ophthalmoscopy, and the gross appearance was unremarkable and showed no change of RPE pigmentation or accumulations (data not shown).
|
|
|
| Discussion |
|---|
|
|
|---|
Elovl4 mRNA levels in Elovl4+/ retina were significantly lower than those in age-matched C57BL/6 mice. The rhodopsin mRNA level was, on average, 33% lower in Elovl4+/ retinas. Although this difference was not statistically significant, it could reflect a decreased requirement for rhodopsin brought about by the slightly reduced number of rods and reduced ROS length.
Despite the 20% decrease in ROS length and the approximately 10% loss of photoreceptor cells, retinal ERG responses of the Elovl4+/ mice were not significantly different from the littermate control mice and, if anything, the responses tended to be larger than WT. ERG responses in ELOVL4+/ patients are generally only slightly smaller than normal, consistent with involvement of only macular function rather than having full-field retinal involvement.3 4 This finding is dissimilar to that in autosomal recessive STGD1 patients, who, because of ABCR gene mutations, can exhibit severe functional deficits across the entire retina.35 36
The amino acid sequence of ELOVL4 is well conserved evolutionarily from yeast to human.18 Members of the ELO family are believed to be involved in fatty acid elongation.37 38 ELOVL4 is expressed in the photoreceptor cells in a number of species.18 In the mouse the retina, brain, testis, and skin express high amounts of Elovl4, and these tissues are known to have high requirements for LCFAs in their cellular membranes.21 Elovl4 expression increases in the retina during the period that photoreceptor outer segments are developing, and a high level of ELOVL4 is maintained throughout life, perhaps because of the requirement for LCFAs in the retina, owing to turnover of photoreceptor outer segment membrane as they undergo repetitive, daily shedding and renewal.39 Very-long-chain polyunsaturated fatty acids of phosphatidylcholine are synthesized in photoreceptors.40 Moreover, lower blood levels of DHA and other long-chain fatty acids have been noted in patients with several different genetic forms of photoreceptor degeneration.41 42 We evaluated but did not find any abnormalities in blood fatty acid composition of the Elovl4+/ mice, despite reduced concentration of several fatty acids in the retina. Although we could discern no obvious pattern in the reduced fatty acids that would place the ELOVL4 enzyme along the fatty acid metabolic pathway in the retina, two LCFAs of 24 carbon atoms were diminished, suggesting that the ELOVL4 protein may be necessary for their synthesis. It was intriguing to note that retinal levels of several shorter fatty acids were also decreased in the Elovl4+/ retinas. LCFAs are broken down and recycled into short-chain nonessential fatty acids, and it is possible that a decrease in long- or very-LCFAs results in lower amounts of short-chain fatty acids. Shortening of the outer segments and photoreceptor loss would reduce the proportion of membrane-rich tissue in the Elovl4+/ retinas relative to the WT and may therefore account for some of the reduced fatty acid content in the Elovl4+/ retinas. However, in such case we would expect the content of DHA, which is the prominent fatty acid in the disc membranes, to be reduced. Because DHA levels were similar in Elovl4+/ and in WT retinas, we suggest that most of the difference in fatty acid content reflects an actual change in fatty acid composition and is not an artifact of different membrane contents in the retinal tissues.
Lower concentrations of monounsaturated fatty acids were noted in the retina of the Elovl4+/ mice. Monounsaturated fatty acids, including specifically oleic acid (18:1n9), have a high affinity for the interphotoreceptor retinoid-binding protein (IRBP) and may be involved in regulating the binding of all-trans-retinol to IRBP.43 Hence, a defect in ELOVL4 activity may have both regulatory and structural consequences. Further work is needed to establish the role of ELOVL4 in fatty acid metabolism in the retina.
Two other Elovl4 mutant mouse models have been produced, both of which are different from this gene-knockout model. One was a transgenic model in which one or more gene copies of mutant Elovl4 with a 5-bp deletion were added to the complement of two endogenous normal gene alleles, causing expression of three and in some cases more copies.12 A second model is a gene-knockin model in which a mutant Elovl4 gene harboring a 5-bp deletion identical with the mutation identified in humans with autosomal dominant STGD3 maculopathy replaces one normal WT allele. The third model that we present here, the Elovl4 knockout, provides unique information as to the possible disease mechanism.
Autosomal dominant human STGD3 disease could hypothetically lead to photoreceptor degeneration through several mechanisms. Haploinsufficiency may result for conditions in which expression of both gene copies is necessary to produce a sufficient quantity of protein to maintain normal function. Because the metabolic requirement for ELOVL4 due to the high level of photoreceptor turnover in the retina may be greater than in other tissues, the loss of one functional allele may make the retinal tissue more susceptible to damage and degeneration than it does other tissues with lower metabolic requirements. One example of haploinsufficiency is the heterozygous rhodopsin knockout rho+/ mouse in which an age-dependent loss of photoreceptors and shortening of rod outer segments are observed as early as 3 to 4 months of age.44 45 By 1 year of age, ONL width and outer segment length in rho+/ mice were reduced to only 50% of wild-type animals, and the ERG b-wave was 80% reduced (Bush R, unpublished observation, 1999). Another example is haploinsufficiency of the rds/peripherin photoreceptor protein that results in abnormal photoreceptor structure and progressive degeneration in the rds+/ mouse.46 47 However, if haploinsufficiency were the underlying mechanism of STGD3 disease, our heterozygous Elovl4+/ mice that expressed greatly reduced Elovl4 message levels would be likely to manifest overt retinal disease. Further, they would have the same phenotype as heterozygous mice harboring the 5-bp deletion human STGD3 mutation. This was not the case, however, as the 5-bp mutation knockin heterozygous mouse is reported to show progressive photoreceptor loss beginning as early as 2 months (Ayyagari R, personal communication, 2005). By contrast, our Elovl4+/ animals showed only subtle structural photoreceptor abnormalities and exhibited no functional ERG abnormality even at the advanced age of 16 months and older, despite the considerable reduction of the normal ELOVL4 message quantity. This is a fundamental difference between the phenotypes of these two models that indicates that retinal degeneration in the STGD3 in mouse does not result primarily from haploinsufficiency.
An alternative mechanism for the autosomal dominant mutation underlying STGD3 is gain of function. A subset of gain-of-function mutations is the dominant negative mechanism, in which the abnormal protein from the mutant allele antagonizes the function of the wild-type protein. Some dominant negative mutations occur in multimeric proteins, in which a single mutant subunit can eliminate normal activity of the entire protein complex.11 In dominant negative disease the heterozygous knockout would have no or a very mild phenotype, as we found in the present Elovl4+/ model.
Elimination or decrease in enzyme activity can lead to abnormal accumulation of a substrate, as occurs in several neurologic disorders involving lysosomal or peroxisomal defects.48 In the case of ELOVL4 disease, a deleterious effect could arise from abnormal accumulation of a precursor fatty acid that is not metabolized appropriately due to insufficient enzymatic activity. However, we did not find evidence toward this in the fatty acid profiles of the Elovl4+/ retinas. It is more likely that the detrimental effect of the mutation involves the lack of some enzymatic product, which would be consistent with the reduced amounts of some fatty acids that we found in the Elovl4+/ retinas.
The present work shows for the first time that haploinsufficiency does not play a key role in the Elovl4 disease mechanism in vivo. Though haploinsufficiency and dominant negative mechanisms are not mutually exclusive, the results of the present study further suggest that the disease observed for the 5-bp deletion ELOVL4 mutation in STGD3 results from a dominant negative mechanism. This mechanism has also been suggested based on in vitro cell line studies and in vivo studies.5 6 7 8 9 10 11 12 13 14 The evidence that is accumulating from the three different Elovl4 mouse models begins to elucidate the disease mechanism in STGD3 and opens the way to exploring treatment strategies.
Finding that haploinsufficiency is not the key mechanism of pathogenesis in STGD3 ELOVL4 disease indicates that decreasing the quantity of mutant protein could be a useful therapeutic strategy. This approach was successful in reducing retinal degeneration in the P23H rhodopsin transgenic rat using ribozyme knockdown of mutant RNA.49 As the Elovl4 transgenic mouse model indicated that disease manifestation worsened as the load of mutant protein increased,12 a strategy of decreasing the ratio of mutant to normal protein should be therapeutically beneficial.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication December 1, 2005; revised March 16, 2006; accepted May 26, 2006.
Disclosure: D. Raz-Prag, None; R. Ayyagari, None; R.N. Fariss, None; M.N.A. Mandal, None; V. Vasireddy, None; S. Majchrzak, None; A.L. Webber, Merck Research Laboratories (E); R.A. Bush, None; N. Salem, Jr, None; K. Petrukhin, Merck Research Laboratories (E); P.A. Sieving, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Paul A. Sieving, National Eye Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 6A03, MSC 2510, Bethesda, MD 20892; paulsieving{at}nei.nih.gov.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M.-P. Agbaga, R. S. Brush, M. N. A. Mandal, K. Henry, M. H. Elliott, and R. E. Anderson Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids PNAS, September 2, 2008; 105(35): 12843 - 12848. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vasireddy, Y. Uchida, N. Salem Jr, S. Y. Kim, M. N. A. Mandal, G. B. Reddy, R. Bodepudi, N. L. Alderson, J. C. Brown, H. Hama, et al. Loss of functional ELOVL4 depletes very long-chain fatty acids (>=C28) and the unique {omega}-O-acylceramides in skin leading to neonatal death Hum. Mol. Genet., March 1, 2007; 16(5): 471 - 482. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |